Virological and clinical aspects of HBV-HCV coinfection in HIV positive patients
✍ Scribed by Pietro Filippini; Nicola Coppola; Raffaella Pisapia; Salvatore Martini; Cecilia Marrocco; Filomena Di Martino; Caterina Sagnelli; Alberico Filippini; Evangelista Sagnelli
- Publisher
- John Wiley and Sons
- Year
- 2007
- Tongue
- English
- Weight
- 124 KB
- Volume
- 79
- Category
- Article
- ISSN
- 0146-6615
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
In a long‐term follow‐up study the clinical and virological presentation of HBV/HCV coinfection in anti‐HIV positive patients was evaluated. Plasma HBV‐DNA, HCV‐RNA, and HIV‐RNA were determined by PCR in 5 HBsAg/anti‐HCV/anti‐HIV positive patients, in 4 HBsAg/anti‐HIV positive patients and in 82 anti‐HCV/anti‐HIV positive patients first observed at a Unit of Infectious Diseases in Naples (Italy) from 1990 to 2000 (follow up 6–16 years). All five hepatitis B and C coinfected patients showed reciprocal inhibition of viral replication on admission and during the follow up. At the end of the follow up a clearance of HBsAg from serum was observed in four patients and a clearance of anti‐HCV in one of them. In two patients after clearance of HBsAg, evidence of occult HBV infection was observed, at times associated with a hepatic flare. None of the four patients with HIV/HBV coinfection lost HBsAg and none of the 82 with HIV/HCV coinfection lost anti‐HCV during the follow up. In anti‐HIV positive patients HBV/HCV coinfection is characterized by reciprocal inhibition of viral replication, more evident in HBV expression in plasma and at times by progression to occult HBV infection. J. Med. Virol. 79:1679–1685, 2007. © 2007 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
## Abstract Migratory processes have caused changes in human immunodeficiency virus (HIV) epidemiology and non‐B subtypes are now playing an increasing role. In a cohort of 553 HIV‐infected outpatients tested to identify non‐B isolates, the largest group consisted of 13 subjects with a recombinant
Liver biopsy remains the gold standard in the assessment of severity of liver disease. Noninvasive tests have gained popularity to predict histology in view of the associated risks of biopsy. However, many models include tests not readily available, and there are limited data from patients with HIV/